Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GLPG Stock Summary
Top 10 Correlated ETFs
GLPG
In the News
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
New Strong Buy Stocks for December 13th
TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.
Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.
Galapagos Stands Strong On Jyseleca Positive Clinical Data
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .
GLPG Financial details
GLPG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 14.67 | 7.35 | 7.4 | 7.7 | 3.63 | |
Net income per share | 2.6 | -4.78 | -1.91 | -3.32 | 3.21 | |
Operating cash flow per share | 55.69 | -6.57 | -7.69 | -7.62 | 0 | |
Free cash flow per share | 54.9 | -7.97 | -8.58 | -8.19 | 0 | |
Cash per share | 100.34 | 79.33 | 71.8 | 62.35 | 0 | |
Book value per share | 49.91 | 41.04 | 40.36 | 38.47 | 0 | |
Tangible book value per share | 49.48 | 40 | 39.44 | 35.18 | 0 | |
Share holders equity per share | 49.91 | 41.04 | 40.36 | 38.47 | 0 | |
Interest debt per share | 0.46 | 0.6 | 0.59 | 0.44 | 0 | |
Market cap | 10.59B | 5.27B | 3.19B | 2.73B | 2.43B | |
Enterprise value | 8.75B | 3.16B | 982.02M | 2.25B | 0 | |
P/E ratio | 70.66 | -16.94 | -25.42 | -12.53 | 11.46 | |
Price to sales ratio | 12.53 | 11.02 | 6.58 | 5.41 | 10.12 | |
POCF ratio | 3.3 | -12.33 | -6.33 | -5.46 | 0 | |
PFCF ratio | 3.35 | -10.16 | -5.68 | -5.08 | 0 | |
P/B Ratio | 3.68 | 1.97 | 1.21 | 1.08 | 0 | |
PTB ratio | 3.68 | 1.97 | 1.21 | 1.08 | 0 | |
EV to sales | 10.36 | 6.61 | 2.03 | 4.44 | 0 | |
Enterprise value over EBITDA | 22.43 | -19.11 | -7.12 | -11.57 | 0 | |
EV to operating cash flow | 2.73 | -7.4 | -1.95 | -4.49 | 0 | |
EV to free cash flow | 2.77 | -6.1 | -1.75 | -4.18 | 0 | |
Earnings yield | 0.01 | -0.06 | -0.04 | -0.08 | 0.09 | |
Free cash flow yield | 0.3 | -0.1 | -0.18 | -0.2 | 0 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Debt to assets | 0 | 0.01 | 0.01 | 0 | 0 | |
Net debt to EBITDA | -4.71 | 12.73 | 15.99 | 2.51 | 0 | |
Current ratio | 10.26 | 8.45 | 8.58 | 8.11 | 0 | |
Interest coverage | 284.4 | -19.03 | -14.21 | -38.4 | 0 | |
Income quality | 21.41 | 1.4 | 4.88 | 2.3 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.08 | 0.2 | 0.2 | 0.37 | 0 | |
Research and developement to revenue | 0.51 | 1.1 | 1.01 | 1.02 | 1.01 | |
Intangibles to total assets | 0 | 0.01 | 0.01 | 0.05 | 0 | |
Capex to operating cash flow | -0.01 | 0.21 | 0.11 | 0.07 | 0 | |
Capex to revenue | -0.05 | -0.19 | -0.12 | -0.07 | 0 | |
Capex to depreciation | -3.67 | -4.89 | -1.67 | -0.56 | 0 | |
Stock based compensation to revenue | 0.05 | 0.17 | 0.15 | 0.18 | 0 | |
Graham number | 54.04 | 66.44 | 41.7 | 53.61 | 0 | |
ROIC | 0.13 | -0.07 | -0.06 | -0.11 | 0 | |
Return on tangible assets | 0.02 | -0.06 | -0.02 | -0.05 | 0 | |
Graham Net | 45.96 | 34.49 | 34.51 | 30.01 | 0 | |
Working capital | 5.29B | 4.73B | 4.3B | 3.71B | 0 | |
Tangible asset value | 2.85B | 2.6B | 2.58B | 2.31B | 0 | |
Net current asset value | 2.67B | 2.32B | 2.31B | 2.03B | 0 | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Average receivables | 56.82M | 126.75M | 151M | 102.97M | 0 | |
Average payables | 105.27M | 156.91M | 152.81M | 133.8M | 0 | |
Average inventory | 265.5K | 305K | 10.46M | 36.75M | 0 | |
Days sales outstanding | 34.6 | 132.39 | 96.81 | 55.87 | 0 | |
Days payables outstanding | 121.73 | 119.41 | 30.09K | 4.03K | 0 | |
Days of inventory on hand | 0.22 | 0.25 | 4.61K | 1.6K | 0 | |
Receivables turnover | 10.55 | 2.76 | 3.77 | 6.53 | 0 | |
Payables turnover | 3 | 3.06 | 0.01 | 0.09 | 0 | |
Inventory turnover | 1.68K | 1.48K | 0.08 | 0.23 | 0 | |
ROE | 0.05 | -0.12 | -0.05 | -0.09 | 0 | |
Capex per share | -0.79 | -1.4 | -0.88 | -0.56 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.07 | 1.46 | 2.71 | 2.29 | 1.82 | |
Net income per share | 0.33 | -3.18 | 0.35 | 0.08 | 0.39 | |
Operating cash flow per share | -1.78 | -2.76 | -1.44 | -1.92 | -1.8 | |
Free cash flow per share | -1.95 | -2.88 | -1.5 | -1.98 | -1.85 | |
Cash per share | 66.26 | 62.75 | 60.55 | 59.29 | 57.84 | |
Book value per share | 40.87 | 38.71 | 38.92 | 39.53 | 39.78 | |
Tangible book value per share | 37.62 | 35.4 | 35.72 | 36.38 | 36.71 | |
Share holders equity per share | 40.87 | 38.71 | 38.92 | 39.53 | 39.78 | |
Interest debt per share | 0.41 | 0.25 | 0.28 | 0.21 | 0.28 | |
Market cap | 2.86B | 2.71B | 2.55B | 2.45B | 2.17B | |
Enterprise value | 2.2B | 2.23B | 2.44B | 2.36B | 2.03B | |
P/E ratio | 33.12 | -3.27 | 27.43 | 119.84 | 21.02 | |
Price to sales ratio | 20.97 | 28.53 | 14.24 | 16.31 | 18.1 | |
POCF ratio | -24.42 | -15.09 | -26.84 | -19.5 | -18.28 | |
PFCF ratio | -22.19 | -14.46 | -25.68 | -18.92 | -17.8 | |
P/B Ratio | 1.06 | 1.07 | 0.99 | 0.95 | 0.83 | |
PTB ratio | 1.06 | 1.07 | 0.99 | 0.95 | 0.83 | |
EV to sales | 16.17 | 23.42 | 13.63 | 15.76 | 16.89 | |
Enterprise value over EBITDA | -83.33 | -19.91 | 69.01 | 333.71 | -324.79 | |
EV to operating cash flow | -18.84 | -12.39 | -25.7 | -18.84 | -17.06 | |
EV to free cash flow | -17.12 | -11.87 | -24.59 | -18.28 | -16.61 | |
Earnings yield | 0.01 | -0.08 | 0.01 | 0 | 0.01 | |
Free cash flow yield | -0.05 | -0.07 | -0.04 | -0.05 | -0.06 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 24.69 | 4.35 | -3.06 | -11.67 | 23.27 | |
Current ratio | 8.38 | 8.11 | 7.95 | 8.49 | 8.91 | |
Interest coverage | -8.53 | 24.33 | 10.13 | 7.15 | -7.39 | |
Income quality | -5.43 | 0.87 | -4.09 | -24.59 | -4.6 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.32 | 0.62 | 0.16 | 0.32 | 0.14 | |
Research and developement to revenue | 0.84 | 1.59 | 0.58 | 0.72 | 0.84 | |
Intangibles to total assets | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | |
Capex to operating cash flow | 0.1 | 0.04 | 0.05 | 0.03 | 0.03 | |
Capex to revenue | -0.09 | -0.08 | -0.02 | -0.03 | -0.03 | |
Capex to depreciation | -2 | -0.36 | 0 | -0.21 | 0.17 | |
Stock based compensation to revenue | 0.14 | 0.39 | 0 | 0.18 | -0.23 | |
Graham number | 17.35 | 52.59 | 17.56 | 8.33 | 18.73 | |
ROIC | -0.01 | -0.05 | 0.01 | 0 | -0.01 | |
Return on tangible assets | 0 | -0.05 | 0.01 | 0 | 0.01 | |
Graham Net | 32.41 | 30.2 | 30.34 | 30.78 | 31.33 | |
Working capital | 3.93B | 3.71B | 3.63B | 3.56B | 3.51B | |
Tangible asset value | 2.48B | 2.31B | 2.35B | 2.38B | 2.42B | |
Net current asset value | 2.18B | 2.03B | 2.09B | 2.09B | 2.13B | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 59.22M | 65.86M | 72.46M | 67.57M | 70.31M | |
Average payables | 157.75M | 144.02M | 144.62M | 143.51M | 126.1M | |
Average inventory | 26.26M | 39.22M | 52.35M | 50.32M | 52.24M | |
Days sales outstanding | 35.93 | 73.18 | 34 | 40.56 | 54.77 | |
Days payables outstanding | 5.82K | 2.9K | 3.93K | 2.76K | 1.91K | |
Days of inventory on hand | 959.42 | 1.15K | 1.3K | 1.03K | 877.97 | |
Receivables turnover | 2.5 | 1.23 | 2.65 | 2.22 | 1.64 | |
Payables turnover | 0.02 | 0.03 | 0.02 | 0.03 | 0.05 | |
Inventory turnover | 0.09 | 0.08 | 0.07 | 0.09 | 0.1 | |
ROE | 0.01 | -0.08 | 0.01 | 0 | 0.01 | |
Capex per share | -0.18 | -0.12 | -0.07 | -0.06 | -0.05 |
GLPG Frequently Asked Questions
What is Galapagos NV stock symbol ?
Galapagos NV is a BE stock and trading under the symbol GLPG
Is Galapagos NV buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $88.89. The lowest prediction is $83.74389562 and the highest is $97
What is GLPG stock prediction ?
What is Galapagos NV stock quote today ?
Galapagos NV stock price is $32.17 today.
Is Galapagos NV stock public?
Yes, Galapagos NV is a publicly traded company.